Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 17;13:2319–2331. doi: 10.2147/OTT.S236860

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Xiu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Expression of TUG1 and its effect on prognosis and radiosensitivity in PCa. (A) The expression of TUG1 was measured by qRT-PCR analysis in PCa tissues (n = 50) or the adjacent non-cancer tissues. (B) The expression of TUG1 was measured by qRT-PCR analysis in human normal prostatic stromal immortalized cell line (WPMY-1) and PCa cell lines (LNCaP, 22RV1, PC-3 and DU145). (C) Survival was analyzed and compared between patients with high and low levels of TUG1 using Kaplan–Meier analysis. (D and E) TUG1 expression was detected in PC-3 and DU145 cells every 3 hrs after 0 or 4 Gy of radiation treatment. *P < 0.05.